Kawasaki Disease
An acute inflammatory illness, mainly in children younger than five, that can damage coronary arteries if not treated promptly.
What causes Kawasaki Disease?
The cause of Kawasaki disease is unknown. It is thought to involve an abnormal immune response in genetically susceptible children, possibly triggered by common environmental or infectious exposures. It is not considered contagious.
Symptoms and what to notice
Persistent fever plus red eyes, rash, red or cracked lips, strawberry tongue, swollen neck lymph node, and red or swollen hands and feet are typical. Irritability, abdominal symptoms, joint pain, and peeling skin can also occur.
How long can it last?
The acute febrile phase usually lasts 1 to 2 weeks without treatment, followed by a subacute phase with peeling and continuing heart risk. Laboratory and heart findings can evolve for weeks, and coronary complications may require lifelong follow-up.
How serious is Kawasaki Disease?
Kawasaki disease can inflame coronary arteries and cause aneurysms, blood clots, myocarditis, valve problems, heart attack, or rarely death. Prompt intravenous immunoglobulin greatly lowers coronary-artery risk.
Treatment and management
Standard treatment is intravenous immunoglobulin plus clinician-directed aspirin. Children at high risk of cardiac complications or with persistent fever may need a second IVIG dose, corticosteroids, or other anti-inflammatory medicines. Coronary aneurysms may require long-term antiplatelet or anticoagulant therapy.
Vaccine: who and when?
No vaccine prevents Kawasaki disease because its cause has not been identified. Routine vaccines should generally continue according to clinician guidance, although live vaccines may need timing adjustments after high-dose IVIG.
Cost note: No vaccine price applies. Hospital, IVIG, echocardiography, cardiology, and follow-up costs vary by disease severity, insurance, and location.
Trusted source
Patient cost varies by insurance, provider, location, and eligibility. Coverage and public-health access differ, so listed prices are examples rather than guaranteed patient prices. This page is for general education and does not replace individualized medical advice, diagnosis, vaccination assessment, or treatment.
Kawasaki Disease: Symptoms, Causes, Treatment, Prevention, and Vaccine Information
Kawasaki disease is a systemic vasculitis of childhood and the leading cause of acquired heart disease among children in many high-income countries. There is no single confirmatory test. Clinicians recognize a pattern of prolonged fever and inflammation while excluding infections and other causes. Treatment is time-sensitive because coronary artery injury can begin during the acute illness, even when a child initially appears to have an ordinary viral infection.
Important: This page is for general education. It does not replace diagnosis, treatment, vaccination advice, or emergency care from a qualified healthcare professional.
Quick Facts
| Topic | Current information |
|---|---|
| Cause | The cause of Kawasaki disease is unknown. It is thought to involve an abnormal immune response in genetically susceptible children, possibly triggered by common environmental or infectious exposures. It is not considered contagious. |
| Main symptoms | Persistent fever plus red eyes, rash, red or cracked lips, strawberry tongue, swollen neck lymph node, and red or swollen hands and feet are typical. Irritability, abdominal symptoms, joint pain, and peeling skin can also occur. |
| Typical course | The acute febrile phase usually lasts 1 to 2 weeks without treatment, followed by a subacute phase with peeling and continuing heart risk. Laboratory and heart findings can evolve for weeks, and coronary complications may require lifelong follow-up. |
| Treatment | Standard treatment is intravenous immunoglobulin plus clinician-directed aspirin. Children at high risk of cardiac complications or with persistent fever may need a second IVIG dose, corticosteroids, or other anti-inflammatory medicines. Coronary aneurysms may require long-term antiplatelet or anticoagulant therapy. |
| Vaccine status | No vaccine prevents Kawasaki disease because its cause has not been identified. Routine vaccines should generally continue according to clinician guidance, although live vaccines may need timing adjustments after high-dose IVIG. |
History and Public-Health Importance
Japanese pediatrician Tomisaku Kawasaki described the syndrome in the 1960s. Subsequent surveillance revealed coronary artery aneurysms as its most important complication. IVIG introduced in the 1980s dramatically lowered coronary risk. Incidence is highest in Japan and among children of East Asian ancestry, but cases occur worldwide in every racial and ethnic group.
What Causes Kawasaki Disease?
The cause of Kawasaki disease is unknown. It is thought to involve an abnormal immune response in genetically susceptible children, possibly triggered by common environmental or infectious exposures. It is not considered contagious.
Kawasaki disease does not spread from child to child. Seasonal clustering and age distribution suggest an environmental or infectious trigger, but no single virus, bacterium, toxin, or exposure explains all cases. Genetics influence susceptibility. Parents did not cause the illness, and isolation of household members is not needed solely because of the diagnosis.
Symptoms and Typical Course
Persistent fever plus red eyes, rash, red or cracked lips, strawberry tongue, swollen neck lymph node, and red or swollen hands and feet are typical. Irritability, abdominal symptoms, joint pain, and peeling skin can also occur.
Classic disease includes at least five days of fever plus four of five findings: bilateral non-purulent red eyes, mouth changes, rash, hand or foot changes, and a cervical lymph node. Incomplete Kawasaki disease has fewer visible criteria but supportive inflammation or coronary changes. Peeling around fingers and toes often appears later. Infants may have subtle signs yet greater coronary risk.
Complications and Who Is at Higher Risk
Kawasaki disease can inflame coronary arteries and cause aneurysms, blood clots, myocarditis, valve problems, heart attack, or rarely death. Prompt intravenous immunoglobulin greatly lowers coronary-artery risk.
Inflammation can weaken coronary artery walls and create dilation or aneurysms. Abnormal vessels can develop clots or narrowing and, rarely, cause heart attack. Myocarditis, pericardial effusion, valve leakage, shock, macrophage activation syndrome, hearing changes, or gallbladder inflammation may occur. Cardiac risk determines the intensity and duration of follow-up.
How It Is Diagnosed
Evaluation includes physical examination, inflammatory markers, blood counts, liver tests, urine testing, and an echocardiogram with coronary measurements. No normal early echocardiogram completely excludes later changes, so repeat imaging is often scheduled. Clinicians distinguish Kawasaki disease from scarlet fever, measles, toxic shock, drug reactions, juvenile inflammatory disease, and multisystem inflammatory syndrome after SARS-CoV-2 infection.
Treatment and Recovery
Standard treatment is intravenous immunoglobulin plus clinician-directed aspirin. Children at high risk of cardiac complications or with persistent fever may need a second IVIG dose, corticosteroids, or other anti-inflammatory medicines. Coronary aneurysms may require long-term antiplatelet or anticoagulant therapy.
IVIG at 2 g/kg is standard initial therapy and is most effective when given promptly, generally within the first ten days. Aspirin dosing and duration are managed by the clinical team; caregivers should never start aspirin on their own. Persistent or recurrent fever after IVIG may lead to repeat IVIG, corticosteroids, infliximab, or other immunomodulation. Children with aneurysms may need antiplatelet or anticoagulant therapy and activity guidance.
Vaccine Information
No vaccine prevents Kawasaki disease because its cause has not been identified. Routine vaccines should generally continue according to clinician guidance, although live vaccines may need timing adjustments after high-dose IVIG.
There is no Kawasaki vaccine. IVIG can reduce immune responses to live vaccines such as measles-mumps-rubella and varicella for a period, so the pediatrician may postpone them according to the dose and current immunization guidance. Inactivated vaccines are handled differently. Individual scheduling should be documented rather than abandoning routine vaccination.
Prevention
Because the trigger is unknown, there is no proven way to prevent onset. Prevention focuses on recognizing persistent fever, obtaining urgent evaluation, treating early, and completing cardiology follow-up. Families should keep records of IVIG timing, echocardiograms, coronary measurements, and medicine plans.
When to Seek Medical Care
A child with fever lasting five days plus red eyes, rash, mouth changes, swollen hands or feet, or a neck node needs urgent evaluation. Seek emergency care sooner for breathing difficulty, chest pain, fainting, shock, extreme lethargy, or inability to drink.
Frequently Asked Questions
Is Kawasaki disease contagious?
No. Cases may cluster seasonally, but the illness is not known to pass directly between people.
Can a child have Kawasaki disease without every classic sign?
Yes. Incomplete disease is particularly important in infants and can still affect the coronary arteries.
Why is IVIG given quickly?
Prompt IVIG markedly reduces the chance of coronary artery aneurysms and controls inflammation.
Can children recover completely?
Most do, especially with early treatment. Coronary findings determine whether short-term or lifelong cardiology follow-up is needed.
Key Takeaway
Persistent fever with the Kawasaki pattern is a pediatric urgency. Early IVIG and structured heart follow-up prevent most serious outcomes even though the underlying cause remains unknown.
Medical, treatment, and vaccine information was reviewed against official U.S. public-health guidance available through September 2026.